Search research articles
Contact Us
Filters
Showing results (41-50 of 287) with videos related to
Page
of 29
Sort By:
Current Gastroenterology Reports
|
November 14, 2008
Optimizing treatment of inflammatory bowel diseases with biologic agents
Gert Van Assche, Séverine Vermeire, Paul Rutgeerts
Current Opinion in Gastroenterology
|
June 1, 2012
Classification of inflammatory bowel disease: the old and the new
Severine Vermeire, Gert Van Assche, Paul Rutgeerts
Nature Clinical Practice. Gastroenterology & Hepatology
|
December 6, 2005
The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases
Séverine Vermeire, Gert Van Assche, Paul Rutgeerts
Expert Opinion on Medical Diagnostics
|
March 19, 2013
Role of biomarkers in the diagnosis of inflammatory bowel disease
Severine Vermeire, Gert Van Assche, Paul Rutgeerts
Core Evidence
|
January 12, 2011
Infliximab: the evidence for its place in therapy in ulcerative colitis
Gert Van Assche, Séverine Vermeire, Paul Rutgeerts
Gut
|
December 17, 2009
Predicting the response to infliximab from trough serum levels
Paul Rutgeerts, Severine Vermeire, Gert Van Assche
Inflammatory Bowel Diseases
|
January 19, 2007
Endoscopic therapy of strictures in Crohn's disease
Gert Van Assche, Séverine Vermeire, Paul Rutgeerts
Inflammatory Bowel Diseases
|
September 26, 2008
What is the role of endoscopy in predicting Crohn's disease relapse or course?
Paul Rutgeerts, Severine Vermeire, Gert Van Assche
Current Opinion in Gastroenterology
|
June 9, 2006
Safety issues with biological therapies for inflammatory bowel disease
Gert Van Assche, Séverine Vermeire, Paul Rutgeerts
Gastroenterology Clinics of North America
|
November 30, 2006
Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies
Gert Van Assche, Séverine Vermeire, Paul Rutgeerts
Page
of 29
Search research articles
Search
Showing results (41-50 of 287) with videos related to
Sort By:
Page
of 29
Current Gastroenterology Reports
|
November 14, 2008
Optimizing treatment of inflammatory bowel diseases with biologic agents
Gert Van Assche, Séverine Vermeire, Paul Rutgeerts
Current Opinion in Gastroenterology
|
June 1, 2012
Classification of inflammatory bowel disease: the old and the new
Severine Vermeire, Gert Van Assche, Paul Rutgeerts
Nature Clinical Practice. Gastroenterology & Hepatology
|
December 6, 2005
The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases
Séverine Vermeire, Gert Van Assche, Paul Rutgeerts
Expert Opinion on Medical Diagnostics
|
March 19, 2013
Role of biomarkers in the diagnosis of inflammatory bowel disease
Severine Vermeire, Gert Van Assche, Paul Rutgeerts
Core Evidence
|
January 12, 2011
Infliximab: the evidence for its place in therapy in ulcerative colitis
Gert Van Assche, Séverine Vermeire, Paul Rutgeerts
Gut
|
December 17, 2009
Predicting the response to infliximab from trough serum levels
Paul Rutgeerts, Severine Vermeire, Gert Van Assche
Inflammatory Bowel Diseases
|
January 19, 2007
Endoscopic therapy of strictures in Crohn's disease
Gert Van Assche, Séverine Vermeire, Paul Rutgeerts
Inflammatory Bowel Diseases
|
September 26, 2008
What is the role of endoscopy in predicting Crohn's disease relapse or course?
Paul Rutgeerts, Severine Vermeire, Gert Van Assche
Current Opinion in Gastroenterology
|
June 9, 2006
Safety issues with biological therapies for inflammatory bowel disease
Gert Van Assche, Séverine Vermeire, Paul Rutgeerts
Gastroenterology Clinics of North America
|
November 30, 2006
Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies
Gert Van Assche, Séverine Vermeire, Paul Rutgeerts
Page
of 29